Download PDF

1. Company Snapshot

1.a. Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.


It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1.The company was formerly known as CycloPorters, Inc.and changed its name to Entrada Therapeutics, Inc.


in October 2017.Entrada Therapeutics, Inc.was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Show Full description

1.b. Last Insights on TRDA

Entrada Therapeutics' recent performance was negatively impacted by its Q2 loss, which lagged revenue estimates. The company's quarterly loss of $1.04 per share was wider than the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $1.55 per share a year ago. Additionally, the company's leadership team expansion and inducement grants to new employees may not have been enough to offset the negative earnings surprise. The company's cash runway is expected to last into Q2 2027, with $354 million in cash, cash equivalents, and marketable securities as of June 30, 2025.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec -04

Source: globenewswire.com

Card image cap

Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts

Nov -17

Source: seekingalpha.com

Card image cap

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates

Nov -06

Source: zacks.com

Card image cap

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Nov -06

Source: globenewswire.com

Card image cap

Entrada Therapeutics to Present at Upcoming Investor Conferences

Oct -28

Source: globenewswire.com

Card image cap

Entrada Therapeutics, Inc. - Special Call

Sep -25

Source: seekingalpha.com

Card image cap

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Sep -05

Source: globenewswire.com

Card image cap

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep -02

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.00%)

6. Segments

Endosomal Escape Vehicle Therapeutics

Expected Growth: 13%

Entrada Therapeutics' Endosomal Escape Vehicle Therapeutics exhibits 13% growth driven by increasing adoption in gene therapy, rising demand for targeted drug delivery, and advancements in nanotechnology. Additionally, partnerships with pharmaceutical companies and growing investments in research and development contribute to the segment's growth.

7. Detailed Products

Endosomal Escape Vehicle (EEV) Platform

A proprietary, intracellular biologics platform that enables the efficient delivery of large molecules, such as proteins and antibodies, into the cytosol of target cells.

Intracellular Biologics

A class of therapeutics that leverage the EEV platform to deliver biologics, such as antibodies and enzymes, directly into the cytosol of target cells.

Nanoparticle-based Delivery

A technology that utilizes nanoparticles to deliver therapeutic payloads, such as small molecules and biologics, to specific cells and tissues.

8. Entrada Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Entrada Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for diseases. However, the company's focus on developing novel therapies may reduce the impact of substitutes.

Bargaining Power Of Customers

Entrada Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients. The company's focus on developing novel therapies may also reduce the bargaining power of customers.

Bargaining Power Of Suppliers

Entrada Therapeutics, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services. However, the company's dependence on a few key suppliers may increase the bargaining power of suppliers.

Threat Of New Entrants

Entrada Therapeutics, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the availability of funding for startups. The company's focus on developing novel therapies may reduce the threat of new entrants.

Intensity Of Rivalry

Entrada Therapeutics, Inc. operates in a highly competitive industry with many established players. The company's focus on developing novel therapies may increase the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 21.97%
Debt Cost 3.95%
Equity Weight 78.03%
Equity Cost 2.03%
WACC 2.45%
Leverage 28.15%

11. Quality Control: Entrada Therapeutics, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Mirum Pharmaceuticals

A-Score: 5.3/10

Value: 6.2

Growth: 7.6

Quality: 3.4

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Entrada Therapeutics

A-Score: 4.7/10

Value: 8.2

Growth: 8.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Karyopharm Therapeutics

A-Score: 3.8/10

Value: 9.8

Growth: 5.8

Quality: 6.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Spyre Therapeutics

A-Score: 3.6/10

Value: 6.8

Growth: 6.8

Quality: 5.6

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Vaxart

A-Score: 3.1/10

Value: 8.2

Growth: 4.3

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Palisade Bio

A-Score: 2.7/10

Value: 6.4

Growth: 5.7

Quality: 3.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

10.32$

Current Price

10.32$

Potential

-0.00%

Expected Cash-Flows